By Dustin Marlan — 2021
The latest frontier in state and local drug reform has been the loosening of legal restrictions on psilocybin—the psychoactive compound in “magic mushrooms.”
Read on theappeal.org
CLEAR ALL
The antidepressant effects of the psychedelic brew known as ayahuasca appear to be related to anti-inflammatory activity, according to new research from scientists in Brazil.
1
Using pharmacokinetic modeling and DMT blood sampling data, we demonstrate that the unique pharmacological characteristics of DMT, which also include a rapid onset and lack of acute tolerance to its subjective effects, make it amenable to administration by target-controlled intravenous infusion.
Taken together, our results suggest that psychedelic microdosing may alleviate symptoms of mood and anxiety disorders, though the potential hazards of this practice warrant further investigation.
These results support a recent model proposing that psychedelics reduce the ‘precision-weighting of priors’, thus altering the balance of top-down versus bottom-up information passing.
The benefits of controlled psilocybin use and spiritual practice on people's well-being long outlast the high, researchers find.
Research into psychedelics, shut down for decades, is now yielding exciting results.
2
Last month, Ian McCall told HBO’s Real Sports that his 17 years in mixed martial arts led him to a painkiller addiction. “I was medicated and so numbed out from such a young age, I turned into a monster,” he told correspondent David Scott.
Williams is the co-lead author of a recent retrospective study that found those who tried doses of psilocybin (more commonly known as magic mushrooms), LSD, or MDMA (the pure substance found in Ecstasy or Molly) reported a decrease in trauma symptoms, depression and anxiety after 30 days.
Regulators will soon grapple with how to safely administer powerful psychedelics for treating depression and post-traumatic stress disorder.
The Food and Drug Administration (FDA) has approved the design of two Phase 3 clinical trials of MDMA for treating PTSD, according to the Multidisciplinary Association for Psychedelic Studies (MAPS), which is funding and leading the clinical trials.